| Name | Title | Contact Details |
|---|
Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.
The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.
Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.